Skip to Content
Merck
All Photos(1)

Documents

D-916

Supelco

N-Desmethylclomipramine hydrochloride solution

1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C18H21ClN2 · HCl
CAS Number:
29854-14-6
Molecular Weight:
337.29
EC Number:
200-659-6
MDL number:
MFCD00792880
UNSPSC Code:
41116107
PubChem Substance ID:
329798895
NACRES:
NA.24

grade

certified reference material

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in methanol (as free base)

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

storage temp.

−20°C

SMILES string

ClC1=CC2=C(C=C1)CCC3=C(C=CC=C3)N2CCCNC.[H]Cl

InChI

1S/C18H21ClN2.ClH/c1-20-11-4-12-21-17-6-3-2-5-14(17)7-8-15-9-10-16(19)13-18(15)21;/h2-3,5-6,9-10,13,20H,4,7-8,11-12H2,1H3;1H

InChI key

KMDDAZOLOSKTKZ-UHFFFAOYSA-N

Related Categories

General description

N-Desmethylclomipramine is a primary plasma metabolite of the tricyclic antidepressant clomipramine. Clomipramine is a tricyclic antidepressant used to treat many conditions from major depression and panic disorder to narcolepsy and obsessive compulsion disorder (OCD). This Certified Snap-N-Spike® Solution is applicable for use in urine drug testing, clinical toxicology, or forensic analysis by LC-MS/MS or GC/MS.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Signal Word

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Target Organs

Eyes

Storage Class Code

3 - Flammable liquids

WGK

WGK 1

Flash Point(F)

49.5 °F - closed cup

Flash Point(C)

9.7 °C - closed cup

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Clinical pharmacology and therapeutics, 66(2), 152-165 (1999-08-25)
To examine the problems of establishing dose-effect and concentration-effect relationships of antidepressant therapy with clomipramine. This randomized double-blind study compared five fixed doses of clomipramine hydrochloride: 25, 50, 75, 125, and 200 mg/day in hospitalized or day patients at nine
O Dale et al.
Veterinary and human toxicology, 36(4), 309-310 (1994-08-01)
A 27-y-old male was admitted deeply comatosed 5-6 h after taking approximately 15 g clomipramine. The prominent feature of the case was a biphasic course of clomipramine and desmethylclomipramine serum concentrations, possibly caused by delayed drug absorption. Clinically, 2 serious
F Coudoré et al.
Journal of analytical toxicology, 20(2), 101-105 (1996-03-01)
A rapid and efficient high-performance liquid chromatographic method using a reversed-phase eluent of methanol-water with butylamine on a silica column was developed for the separation and quantitation of clomipramine (CMI), its demethylated metabolites (desmethyl-clomipramine and didesmethyl-clomipramine [DDCMI]), and its hydroxylated
K L Wisner et al.
The Journal of clinical psychiatry, 56(1), 17-20 (1995-01-01)
Women with postpartum-onset obsessive compulsive disorder may elect treatment with clomipramine. There is minimal information to guide the clinician who must advise breastfeeding women about clomipramine therapy. Four clomipramine-treated breastfeeding mother-infant pairs were assessed for serum concentrations of clomipramine, N-desmethylclomipramine
N Ueda et al.
Psychiatry and clinical neurosciences, 54(6), 669-672 (2001-01-06)
The aim of this paper is to describe two cases of clomipramine-induced delirium. One 61-year-old and one 67-year-old female depressive patients became delirious after beginning intravenous clomipramine injections in addition to their oral clomipramine administrations. Their plasma levels of both
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service